{'fraction_non_alphanumeric': 0.016791044776119403, 'fraction_numerical': 0.0065298507462686565, 'mean_word_length': 5.131428571428572, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
STATIN THERAPY IS ASSOCIATED WITH REDUCED NEUROPATHOLOGIC CHANGES OF ALZHEIMER DISEASE

penetrance.” No other family members were available for study. To date, this remains the only report of a truncating LRRK2 mutation identified among the thousands of patients with PD and controls who have been sequenced at the LRRK2 locus. Nonetheless, this identified change cannot be overlooked and if shown to be a disease-causing mutation would certainly necessitate alteration of the current hypothesis as to the mechanism by which LRRK2 mutations lead to PD. As pointed out by Bonifati et al., another article that was just recently published (after acceptance of our manuscript) suggests that loss of LRRK2 function induces degeneration of dopaminergic neurons in Drosophila.4 As we stated and was echoed by Bonifati et al., an accurate determination of the pathogenicity of newly identified LRRK2 variants is important not only for the counseling of patients and at risk individuals, but in helping to establish mechanisms whereby mutations/variants in LRRK2 can result in PD.